# A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

> **NCT07743164** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 646 (estimated)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **BIOLOGICAL:** R-DXd
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Pegylated liposomal doxorubicin (PLD)

## Key facts

- **NCT ID:** NCT07743164
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-05
- **Primary completion:** 2031-08-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 646 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743164, "A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT07743164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*